Dr Rachel Giles guides us through 7 abstracts from the MTIS Virtual Symposium 2020:
- OVERCOME study: Improvement of migraine using CGRP mAbs in a real-world setting. Shapiro et al.
- Remote electrical neuromodulation useful for adolescents with migraine. Hershey et al.
- GLADIATOR trial: No new cardiovascular safety concerns with long-term use of lasmiditan. Hochstetler
- CONQUER trial: Less medication use and doctor visits with galcanezumab in treatment-resistant migraine. Gomez et al.
- TELESCOPE trial: Real-world evidence reveals physicians’ perception of erenumab. Koch et al.
- FOCUS and HALO studies: Fremanezumab effective in patients with migraine and comorbid depression
- PREDICT trial: Long-term onabotulinumtoxinA improves quality of life in migraine
Posted on
Table of Contents: MTIS 2020
Featured articles
Contents
Improvement of migraine using CGRP mAbs in a real-world setting
Similar treatment needs for high-frequency episodic and low-frequency chronic migraine
Nitroglycerin-induced cluster headache attacks characterised comprehensively
Remote electrical neuromodulation useful for adolescents with migraine
Concomitant preventive medication has no impact on efficacy of ubrogepant
No new cardiovascular safety concerns with long-term use of lasmiditan
Less medication use and fewer doctor visits with galcanezumab in treatment-resistant migraine
Real-world evidence reveals physicians’ perception of erenumab
Early initiation of lasmiditan improves migraine outcomes
Fremanezumab effective in patients with migraine and comorbid depression
Long-term onabotulinumtoxinA improves quality of life in migraine
Sustained shift in migraine status using galcanezumab
Long-term efficacy and safety of fremanezumab in treatment-resistant migraine
site created by:
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy